Bioengineered Alternative Tissues and Hyperbaric Oxygen in Lower Extremity Wound Healing

Clinics in Podiatric Medicine and Surgery

Volumn 24, Issue 3, 2007, Pages 529-546

  Kim, Paul J ^a,b   Heilala, Matt ^a,c   Steinberg, John S ^a,d   Weinraub, Glenn M ^a,e  

^a Foot and Ankle Institute   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c Center for Wound Healing ^*  (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECAPLERMIN; BIOBRANE; BIOMATERIAL; CHONDROITIN 6 SULFATE; COLLAGEN; COLLAGEN TYPE 1; GROWTH FACTOR; HYALURONIC ACID; NYLON; PLATELET DERIVED ANGIOGENESIS FACTOR; PLATELET DERIVED GROWTH FACTOR; POLYGLACTIN; SILICONE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTIFICIAL SKIN; BILAYER MEMBRANE; CADAVER DONOR; CAST APPLICATION; COLLAGEN DISEASE; COLLAGEN SYNTHESIS; DEBRIDEMENT; DERMIS; DIABETIC FOOT; EPIDERMIS; EPITHELIZATION; EXOSTOSECTOMY; FOOT SURGERY; FOOT ULCER; HEALTH CARE COST; HUMAN; HUMAN CELL CULTURE; HYPERBARIC OXYGEN; INTESTINE MUCOSA; KERATINOCYTE; OXYGEN TENSION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; SKIN AUTOGRAFT; SKIN BIOPSY; SKIN FIBROBLAST; SPLIT THICKNESS SKIN GRAFT; SUBCUTANEOUS TISSUE; SURGICAL EQUIPMENT; SURGICAL TECHNIQUE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA; TISSUE ENGINEERING; TREATMENT INDICATION; TREATMENT OUTCOME; WOUND CLOSURE; WOUND HEALING;

BIOLOGICAL DRESSINGS; BIOMEDICAL ENGINEERING; DIABETIC FOOT; HUMANS; HYPERBARIC OXYGENATION; SALVAGE THERAPY; SKIN, ARTIFICIAL; WOUND HEALING;

EID: 34347407850     PISSN: 08918422     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpm.2007.03.011     Document Type: Review

References (60)

1. Bello Y.M., Falabella A.F., and Eaglstein W.H. Tissue-engineered skin, current status in wound healing. Am J Clin Dermatol 2 5 (2001) 305-313
2. Curran M.P., and Plosker G.L. Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers. BioDrugs 16 6 (2002) 439-455
3. Claxton M.J., Armstrong D.G., and Boulton A.J.M. Healing the diabetic wound and keeping it healed: modalities for the early 21st century. Curr Diab Rep 2 6 (2002) 510-518
4. Dini V., Romanelli M., Piaggesi A., et al. Cutaneous tissue engineering and lower extremity wounds (part 2). Int J Low Extrem Wounds 5 1 (2006) 27-34
5. Harding K.G., Morris H.L., and Patel G.K. Science, medicine and the future: healing of chronic wounds. Br Med J 324 7330 (2002) 160-163
6. Jones I., Currie L., and Martin R. A guide to biological skin substitutes. Br J Plast Surg 55 (2002) 185-193
7. Kirsner R.S., Falanga V., and Eaglstein W.H. The development of bioengineered skin. Trends Biotechnol 16 6 (1998) 246-249
8. Lee K.H. Tissue-engineered human living skin substitutes: development and clinical application. Yonsei Med J 41 6 (2000) 774-779
9. Marston W.A. Dermagraft, a bioengineered human dermal equivalent for the treatment of chronic nonhealing diabetic foot ulcer. Expert Rev Med Devices 1 1 (2004) 21-31
10. Sheehan P., Jones P., Caselli A., et al. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care 26 6 (2003) 1879-1882
11. Attinger C.E., and Bulan E.J. Debridement: the key initial step in wound healing. Foot Ankle Clin 6 (2001) 627-660
12. Brem H., Sheehan P., and Boulton A.J.M. Protocol for treatment of diabetic foot ulcers. Am J Surg 187 Suppl (2004) 1S-10S
13. Akopian G., Nunnery S.P., Piangenti J., et al. Outcomes of conventional wound treatment in a comprehensive wound center. Am Surg 72 4 (2006) 314-317
14. Brem H., Balledux J., Bloom T., et al. Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent. Arch Surg 135 6 (2000) 627-634
15. Brem H., Balledux J., Sukkarieh T., et al. Healing of venous ulcers of long duration with a bilayered living skin substitute: results from a general surgery and dermatology department. Dermatol Surg 27 11 (2001) 915-919
16. Falanga V.J. Tissue engineering in wound repair. Adv Wound Care 13 S2 (2000) 15-19
17. Fivenson D., and Scherschun L. Clinical and economic impact of Apligraft for the treatment of nonhealing venous leg ulcers. Int J Dermatol 42 (2003) 960-965
18. Long R.E., Falabella A.F., Valencia I., et al. Treatment of refractory, atypical lower extremity ulcers with tissue-engineered skin (Apligraf). Arch Dermatol 137 12 (2001) 1660-1661
19. Redekop W.K., McDonnell J., Verboom P., et al. The cost effectiveness of Apligraf treatment of diabetic foot ulcers. Pharmacoeconomics 21 16 (2003) 1171-1183
20. Sams H.H., Chen J., and King L.E. Graftskin treatment of difficult to heal diabetic foot ulcers: one center's experience. Dermatol Surg 28 8 (2002) 698-703
21. Veves A., Falanga V., Armstrong D.G., et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 24 (2001) 290-295
22. Hanft J.R., and Surprenant M.S. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. J Foot Ankle Surg 41 5 (2002) 291-299
23. Allenet B., Parée F., Lebrun T., et al. Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the French context. Diabetes Metab 26 (2000) 125-132
24. Grey J.E., Lowe G., Bale S., et al. The use of cultured dermis in the treatment of diabetic foot ulcers. J Wound Care 7 7 (1998) 324-325
25. Newton D.J., Khan F., Belch J.J.F., et al. Blood flow changes in diabetic foot ulcers treated with dermal replacement therapy. J Foot Ankle Surg 41 4 (2002) 233-237
26. Omar A.A., Mavor A.I.D., Jones A.M., et al. Treatment of venous leg ulcers with Dermagraft. Eur J Vasc Endovasc Surg 27 (2004) 666-672
27. Marston W.A., Hanft J., Norwood P., et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers, results from a prospective randomized trial. Diabetes Care 26 6 (2003) 1701-1705
28. Lobmann R., Pittasch D., Mühlen I., et al. Autologous human keratinocytes cultured on membranes composed of benzyl ester of hyaluronic acid for grafting in nonhealing diabetic foot lesions: a pilot study. J Diabetes Complications 17 (2003) 199-204
29. Boyce S.T., Kagan R.J., Meyer N.A., et al. The 1999 clinical research award: cultured skin substitutes combined with Integra artificial skin to replace native skin autograft and allograft for the closure of full-thickness burns. J Burn Care Rehabil 20 6 (1999) 453-461
30. Heitland A., Piatkowski A., Noah E.M., et al. Update on the use of collagen/glycosaminoglycate skin substitute: six years of experience with artificial skin in 15 German burn centers. Burns 30 (2004) 471-475
31. Michaeli D., and McPherson M. Immunologic study of artificial skin used in the treatment of thermal injuries. J Burn Care Rehabil 11 1 (1990) 21-26
32. Ryan C.M., Shoenfeld D.A., Malloy M., et al. Use of Integra artificial skin is associated with decreased length of stay for severely injured adult burn survivors. J Burn Care Rehabil 23 5 (2002) 311-317
33. Stern R., McPherson M., and Longaker M.T. Histologic study of artificial skin used in the treatment of full-thickness thermal injury. J Burn Care Rehabil 11 1 (1990) 7-13
34. Wisser D., Rennekampff H.O., and Schaller H.E. Skin assessment of burn wounds covered with a collagen based dermal substitute in a 2 year-follow-up. Burns 30 (2004) 399-401
35. Silverstein G. Dermal regeneration template in the surgical management of diabetic foot ulcers: a series of five cases. J Foot Ankle Surg 45 1 (2006) 28-33
36. Molnar J.A., DeFranzo A.J., Hadaegh A., et al. Acceleration of Integra incorporation in complex tissue defects with subatmospheric pressure. Plast Reconstr Surg 113 5 (2004) 1339-1346
37. Violas P., Abid A., Darodes P., et al. Integra artificial skin in the management of severe tissue defects, including bone exposure, in injured children. J Pediatr Orthop B 14 5 (2005) 381-384
38. Wilensky J.S., Rosenthal A.H., Bradford C.R., et al. The use of bovine collagen construct for reconstruction of full-thickness scalp defects in the elderly patient with cutaneous malignancy. Ann Plast Surg 54 3 (2005) 297-301
39. Martin B.R., Sangalang M., Wu S., et al. Outcomes of allogenic acellular matrix therapy in treatment of diabetic foot wounds: an initial experience. Int Wound J 2 2 (2005) 161-165
40. Brigido S.A. The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. Int Wound J 3 3 (2006) 181-187
41. Rosales M.A., Bruntz M., and Armstrong D.G. Gamma-irradiated human skin allograft: a potential treatment modality for lower extremity ulcers. Int Wound J 1 3 (2004) 201-206
42. Walden J.L., Garcia H., Hawkins H., et al. Both dermal matrix and epidermis contribute to an inhibition of wound contraction. Ann Plast Surg 45 2 (2000) 162-166
43. Lattari V., Jones L.M., Varcelotti J.R., et al. The use of a permanent dermal allograft in full-thickness burns of the hand and foot: a report of three cases. J Burn Care Rehabil 18 2 (1997) 147-155
44. Mostow E.N., Haraway G.D., Dalsing M., et al. OASIS Venus Ulcer Study Group. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg 41 5 (2005) 837-843
45. Niezgoda J.A., Van Gils C.C., Frykberg R.G., et al. Oasis Diabetic Ulcer Study Group. Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Adv Skin Wound Care 18 5 (2005) 258-266
46. Mustoe T.A., Pierce G.F., Morisima C., et al. Growth factor induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model. J Clin Invest 87 (1991) 694-703
47. Glover J.L., Weingarten M.S., Buchbinder D.S., et al. A 4-year outcome-based retrospective study of wound healing and limb salvage in patients with chronic wounds. Adv Wound Care 10 1 (1997) 33-38
48. Margolis D.J., Kantor J., Santanna J., et al. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 24 3 (2001) 483-488
49. Driver V.R., Hanft J., Fylling C.P., et al. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage 52 6 (2006) 68-87
50. Atri S.C., Misra J., Bisht D., et al. Use of homologous platelet factors in achieving total healing of recalcitrant skin ulcers. Surgery 108 3 (1990) 508-512
51. Knighton D.R., Ciresi K., Fiegel V.D., et al. Classification and treatment of chronic nonhealing wounds: successful treatment with autologous platelet-derived wound healing factors. Ann Surg 204 3 (1986) 322-330
52. Knighton D.R., Ciresi K., Fiegel V.D., et al. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula. Surg Gynecol Obstet 170 (1990) 56-60
53. Steed D.L., Goslen J.B., Holloway G.A., et al. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers: CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care 15 11 (1992) 1598-1604
54. Crovetti G., Martinelli G., Issi M., et al. Platelet gel for healing cutaneous chronic wounds. Transfus Apher Sci 30 (2004) 145-151
55. Saldalamacchia G., Lapice E., Cuomo V., et al. A controlled study of the use of autologous platelet gel for the treatment of diabetic foot ulcers. Nutr Metab Cardiovasc Dis 14 (2004) 395-396
56. Bert P. Bubble theory. In: Bert P. (Ed). Barometric pressure: researches in experimental physiology [English translation of 1943 edition] (1878), College Book Company, Columbus (OH)
57. Paul Sheffield. Lecture and Manual, Hyperbaric Medicine: A Historical Perspective. Moir E, 1889. HMTT San Antonio, TX, December 5-11, 1999.
58. Boerema I., Meyene N.G., Brummelkamp W.H., et al. Leven zonder bloed. [life without blood]. Ned Tijdschr Geneeska 104 (1960) 949-954 [in Dutch]
59. Davis JC, Hunt TK. Problem wounds, the role of oxygen. 1988.
60. Sheffield PJ. Director of Research and Education, Course Director, Hyperbaric Medicine Team Training, Nix Hospital. San Antonio (TX), December 5-11, 1999.